SY-5609   Click here for help

GtoPdb Ligand ID: 11841

Synonyms: SY-0005609 | SY5609
Compound class: Synthetic organic
Comment: SY-5609 is an orally bioavailable inhibitor of CDK7 that was designed for anti-cancer potential [1]. It is a derivative of mevociclib (SY-1365).
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 3
Rotatable bonds 5
Topological polar surface area 116.3
Molecular weight 490.19
XLogP 4.48
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES N#Cc1ccc2c(c1P(=O)(C)C)[nH]cc2c1nc(ncc1C(F)(F)F)N[C@H]1CCC(NC1)(C)C
Isomeric SMILES CC1(C)CC[C@H](Nc2ncc(c(c3c[nH]c4c3ccc(C#N)c4P(=O)(C)C)n2)C(F)(F)F)CN1
InChI InChI=1S/C23H26F3N6OP/c1-22(2)8-7-14(10-30-22)31-21-29-12-17(23(24,25)26)18(32-21)16-11-28-19-15(16)6-5-13(9-27)20(19)34(3,4)33/h5-6,11-12,14,28,30H,7-8,10H2,1-4H3,(H,29,31,32)/t14-/m0/s1
No information available.
Summary of Clinical Use Click here for help
SY-5609 has advanced to early stage clinical evaluations to determine efficacy as a therapy for solid tumours.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04929223 A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC) Phase 1 Interventional Hoffmann-La Roche
NCT04247126 A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors Phase 1 Interventional Syros Pharmaceuticals